

Competitor Analysis: RORgamma Antagonists and Agonists

https://marketpublishers.com/r/CA21D03DD019EN.html

Date: September 2019

Pages: 28

Price: US\$ 280.00 (Single User License)

ID: CA21D03DD019EN

Abstracts

Competitor Analysis: RORgamma Antagonists and Agonists

This Competitive Intelligence report about RORgamma Antagonists and Agonists evaluates the landscape of investigational small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (ROR?) for treatment of inflammatory diseases and cancer as of September 2019.

The transcription factor ROR? plays a critical role in the expression of pro-inflammatory cytokine interleukin IL-17 and is therefore an attractive target for the treatment of inflammatory diseases. Interest in this molecular target has been heightened by the advancement of orally and topically administered ROR? modulators into clinical trials.

Some studies found ROR? to be upregulated in cancer tissues compared with normal tissues. Furthermore, synthetic ROR? agonists modulate immune cell gene expression to increase effector T-cell activity and decrease immune suppression.

The report includes a compilation of currently active projects in research and development of RORgamma antagonists and agonists for treatment of inflammatory diseases and cancer, respectively. In addition, the report lists company-specific R&D pipelines of antagonists and agonists of RORgamma. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target/Mechanism of Action,



Class	of	Compound	
Ciass	OI.	Compound	٠

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.



Contents

- 1) RORGAMMA ANTAGONISTS/INVERSE AGONISTS FOR INFLAMMATORY DISEASES
- 2) RORGAMMA AGONISTS FOR CANCER
- 3) CORPORATE RORGAMMA ANTAGONIST & AGONIST R&D PIPELINES



I would like to order

Product name: Competitor Analysis: RORgamma Antagonists and Agonists

Product link: https://marketpublishers.com/r/CA21D03DD019EN.html

Price: US\$ 280.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CA21D03DD019EN.html